| Literature DB >> 18635311 |
Marta Albajar1, Pilar Gutierrez, Carlos Richard, Manuel Rosa-Garrido, M Teresa Gómez-Casares, Juan L Steegmann, Javier León, M Dolores Delgado.
Abstract
The PU.1 transcription factor is a crucial regulator of hematopoiesis which expression is altered in various leukemic processes. Our previous work in chronic myeloid leukemia (CML) cells demonstrated that interferon-alpha upregulated PU.1 expression. Here we show that expression of PU.1 is severely impaired in patients with CML at diagnosis. However, the PU.1 suppression is abrogated in patients in remission, after interferon-alpha or imatinib treatment. These effects are not found in patients with other myeloproliferative diseases such as polycythemia vera or essential thrombocythemia. PU.1 could, therefore, be used as an additional marker of the response to the treatment of the CML.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18635311 DOI： 10.1016/j.canlet.2008.05.024
Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679